Modelled supplements for Chronic Obstructive Pulmonary Disease (COPD)
Conventional Beliefs
Vitamin D: Vitamin D deficiency is common in people with COPD and might be associated with exacerbations and reduced lung function. Vitamin D supplementation might be recommended under the guidance of healthcare professionals to address deficiencies and potentially reduce respiratory issues. However, the dosage should be determined by a healthcare provider.
Omega-3 Fatty Acids: Omega-3 supplements containing EPA and DHA have anti-inflammatory properties and might have potential benefits in reducing inflammation and supporting overall health in individuals with COPD. However, evidence supporting their use specifically for COPD management is limited.
Probiotics: Some research suggests that probiotics might have potential benefits for respiratory health by modulating the immune system and reducing respiratory infections. However, evidence supporting their use specifically for COPD is limited, and the specific strains and dosages for respiratory health require further investigation.
Antioxidants: Antioxidant supplements such as vitamin C, vitamin E, or N-acetylcysteine (NAC) might be considered to reduce oxidative stress and inflammation in individuals with COPD. However, the use of antioxidants should be discussed with healthcare providers due to potential interactions with medications and variable effects in COPD.
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance.
Special thanks to Oliver Luk, B.Sc. (Biology) from
BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
